

Trial Status



Happy New Year! Welcome to 2022, we would once again like to express our gratitude and thank you for all your continued hard work and commitment to the APHRODITE trial. Currently, **9** out of the **11** sites are open to recruitment with Bristol and Royal Devon progressing well. The soon to be 12th site, Southampton, are due to be added in the upcoming amendment.


Research Activities

We would like to thank all of the staff at NHS who have been working under a lot of pressure due to COVID-19. There are some research activities that will continue to have time critical deadlines, such as:

- Safety reporting
- Pregnancy reporting
- Providing evidence of consent
- Returning priority validations
- Protocol violations

We ask that you prioritise these activities so we can continue to monitor key aspects of the trial at this time.

APHRODITE site set up



Substantial Amendment 3

Work on substantial amendment 3 to update the protocol continues and will soon be submitted. This amendment will contain some significant changes to the trial including:

- Updates to the central review process and associated documents, please see email sent 21/10/2021 for more information
- Incorporation of the new Yorkshire Cancer Research (YCR) logo into APHRODITE documents
- Southampton included in the APHRODITE trial as the newest site

Please note, as part of the substantial amendment, the current entry criteria will be widened and further details will be provided to sites as soon as possible.

DCE

The APHRODITE patient preference project measures rectal cancer patients' preferences for different aspects of treatment, both before and after experiencing their own treatment. Several centres are currently recruiting participants, with around 15 pre-treatment surveys completed, as well as a couple of post-treatment surveys. The patient preference study will enhance the impact of the clinical trial results, as well as helping future treatment regimes be more patient-centred. If your centre is not already participating, and would like to take part, please contact PatientPreferenceAPHRODITE@leeds.ac.uk or e.j.d.webb@leeds.ac.uk. The APHRODITE patient preference project is formally a separate study from the APHRODITE clinical trial, and has separate CRN portfolio adoption.

MACRO Update

MACRO is now validated for use with Microsoft Edge as well as Internet Explorer 11 and will be implemented at CTRU very soon. Microsoft Edge will be replacing Internet Explorer as the default web browser in Windows and site staff should find that some parts of MACRO will load faster in Edge. Microsoft Edge will also be available for use on Apple Mac devices, but will not be available for use on tablets or mobile phones.

Patients Recruited



At this time the CTRU team are continuing to work primarily from home. If you have any questions or queries about the trial, please contact the APHRODITE trial inbox.

Recruitment

As of January 2022, a total of **14** patients have been recruited, with Glan Clwyd having randomised a total of 9 patients since opening

Want to know more? Then please check out the twitter feed https://twitter.com/aphrodite_trial for healthcare professionals.



If you would like your site to be featured on the newsletter then please let us know about your experience of recruiting into the APHRODITE trial!